- Professor of Psychiatry at Yale School of Medicine and Director of the Schizophrenia Research Program
- Not Clearly Pro or Con to the question "Should Marijuana Be a Medical Option?"
“For most qualifying conditions, approval has relied on low-quality scientific evidence, anecdotal reports, individual testimonials, legislative initiatives, and public opinion. Imagine if other drugs were approved through a similar approach… For most of the conditions that qualify for medical marijuana use, the evidence fails to meet FDA standards…
If the states’ initiative to legalize medical marijuana is merely a veiled step toward allowing access to recreational marijuana, then the medical community should be left out of the process, and instead marijuana should be decriminalized.
Conversely, if the goal is to make marijuana available for medical purposes, then it is unclear why the approval process should be different from that used for other medications. Evidence justifying marijuana use for various medical conditions will require the conduct of adequately powered, double-blind, randomized, placebo/active controlled clinical trials to test its short- and long-term efficacy and safety.”
Cowritten with Mohini Ranganathan, “Medical Marijuana: Is the Cart Before the Horse?,” Journal of the American Medical Association, June 2015
- Involvement and Affiliations:
- Professor of Psychiatry, Yale School of Medicine
- Director Schizophrenia Research Program Veterans Affairs Connecticut Healthcare System (VACHS)
- Director, Neurobiological Studies Unit, VACHS
- Director, Veterans Affairs Schizophrenia Research Clinic
- Interim Chief of Psychiatry, VA Connecticut Healthcare System, 2010
- MD, State University New York at Brooklyn, 1992
- MBBS, St. John’s Medical College (India), 1986
- None found